Abstract
Age‐related macular degeneration (AMD) is a complex genetic disease. At this time, there are over 50 variants in over 30 genetic loci that are associated with various aspects of the disease. The two best studied groups of risk alleles are related to complement factors (especially Complement Factor H or CFH) and the Age‐related Maculopathy Susceptibility 2 (ARMS2)/High‐temperature Requirement A Serine Peptidase 1 (HTRA1) complex. In the opinion of the presenter, at this time there is no convincing evidence of an association between AMD risk allele genotype and clinical outcomes. Therefore, while genetic analysis remains an intriguing area of research, there is currently no role for genetic testing in the routine clinical care of AMD patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
